Production (Stage)
Inhibrx Biosciences, Inc.
INBX
$14.39
$0.473.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -- | -45.09% | -- | -- | -- |
| Total Receivables | -29.61% | -46.02% | -- | -- | -- |
| Inventory | -77.26% | -79.79% | -- | -- | -- |
| Prepaid Expenses | -33.06% | -26.22% | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 32.15% | 9.51% | -- | -- | -- |
| Total Current Assets | 1,475.03% | -45.69% | -- | -- | -- |
|
|
|||||
| Total Current Assets | 1,475.03% | -45.69% | -- | -- | -- |
| Net Property, Plant & Equipment | 31.70% | 44.47% | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 48.34% | 115.90% | -- | -- | -- |
| Total Assets | 759.75% | -41.29% | -- | -- | -- |
|
|
|||||
| Total Accounts Payable | 0.22% | -55.90% | -- | -- | -- |
| Total Accrued Expenses | 28.29% | 18.34% | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -6.80% | -22.69% | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 13.55% | -27.67% | -- | -- | -- |
|
|
|||||
| Total Current Liabilities | 13.55% | -27.67% | -- | -- | -- |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 952.41% | 481.35% | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 280.07% | -82.15% | -- | -- | -- |
|
|
|||||
| Common Stock & APIC | 2,364.49% | -63.53% | -- | -- | -- |
| Retained Earnings | -- | 82.71% | -- | -- | -- |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | 976.91% | 207.07% | -- | -- | -47.53% |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 976.91% | 207.07% | -- | -- | -47.53% |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 976.91% | 207.07% | -- | -- | -47.53% |
|
|
|||||